Sort   by:  
 Page size 
UnknownRefactored M13 bacteriophage as a platform for tumor cell imaging and drug delivery.
Not available
S-EPMC3905571 | biostudies-literature
UnknownChanges in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Not available
S-EPMC4542595 | biostudies-literature
UnknownAn integrated brain-behavior model for working memory.
Not available
S-EPMC5988862 | biostudies-literature
UnknownAltered Stress-Induced Regulation of Genes in Monocytes in Adults with a History of Childhood Adversity.
Not available
S-EPMC4987852 | biostudies-literature
UnknownTixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies.
Not available
S-EPMC11927737 | biostudies-literature
UnknownProteome analysis of monocytes implicates altered mitochondrial biology in adults reporting adverse childhood experiences.
Not available
S-EPMC9889346 | biostudies-literature
UnknownImpact of SARS-CoV-2 Resistance to Antiviral Monoclonal Antibody Therapy on Neutralizing Antibody Response.
Not available
S-EPMC11378757 | biostudies-literature
UnknownSafety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials.
Not available
S-EPMC10134004 | biostudies-literature
UnknownACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.
Not available
S-EPMC10469341 | biostudies-literature
UnknownCharacterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2.
Not available
S-EPMC11326811 | biostudies-literature
Sort   by:  
 Page size